Genpharm is proud to announce that it has entered into an agreement with Ultragenyx for the commercialization and distribution of Mepsevii (vestronidase alfa-vjbk) in the GCC region. Mepsevii is approved by the FDA and the EMA for the treatment of pediatric and adult patients with Mucopolysaccaridosis VII (MPS VII, Sly Syndrome). Mepsevii is the first and only therapy for MPS VII.
Karim Smaira Genpharm’s CEO, “We are very excited to partner with Ultragenyx. We believe that we are a great fit since Genpharm’s mission is to put patients first and bring the most innovative drugs to our region.”
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information, visit https://www.ultragenyx.com/